AP2524A - Amino-heterocyclic compounds - Google Patents
Amino-heterocyclic compoundsInfo
- Publication number
- AP2524A AP2524A AP2009005048A AP2009005048A AP2524A AP 2524 A AP2524 A AP 2524A AP 2009005048 A AP2009005048 A AP 2009005048A AP 2009005048 A AP2009005048 A AP 2009005048A AP 2524 A AP2524 A AP 2524A
- Authority
- AP
- ARIPO
- Prior art keywords
- amino
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91733307P | 2007-05-11 | 2007-05-11 | |
| PCT/IB2008/001125 WO2008139293A1 (en) | 2007-05-11 | 2008-05-05 | Amino-heterocyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2009005048A0 AP2009005048A0 (en) | 2009-12-31 |
| AP2524A true AP2524A (en) | 2012-12-04 |
Family
ID=39672073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2009005048A AP2524A (en) | 2007-05-11 | 2008-05-05 | Amino-heterocyclic compounds |
Country Status (43)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| PE20091211A1 (es) | 2007-11-30 | 2009-09-14 | Boehringer Ingelheim Int | Derivados de pirazolopirimidina como moduladores de pde9a |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| EA201100446A1 (ru) | 2008-09-08 | 2011-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Пиразолопиримидины и их применение для лечения нарушений цнс |
| EP2355822B1 (en) | 2008-11-19 | 2012-10-10 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| AU2010230290B2 (en) | 2009-03-31 | 2013-03-14 | Boehringer Ingelheim International Gmbh | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A modulators |
| JP5808319B2 (ja) * | 2009-05-11 | 2015-11-10 | フォルム ファーマシューティカルズ、インコーポレイテッド | アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療 |
| EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| EP2485771A4 (en) * | 2009-10-08 | 2014-11-12 | Intra Cellular Therapies Inc | TRACER AND METHODS TAGGED ON PHOSPHODIESTERASE 1 |
| RS54742B1 (sr) | 2010-05-17 | 2016-10-31 | Forum Pharmaceuticals Inc | Kristalni oblik (r)-7-hlor-n-(hinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidrohlorid monohidrata |
| DK2603511T3 (en) | 2010-08-12 | 2017-05-08 | Boehringer Ingelheim Int | 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO- [3,4-D] PYRIMIDIN-4-ON DERIVATIVES AND THEIR USES AS PDE9A INHIBITORS |
| PL2615089T3 (pl) | 2010-09-07 | 2016-10-31 | Związki pirazolochinolinowe | |
| JP5855109B2 (ja) * | 2010-09-20 | 2016-02-09 | フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | イミダゾトリアジノン化合物 |
| US20130040971A1 (en) * | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| MY167698A (en) | 2011-10-07 | 2018-09-21 | Eisai R&D Man Co Ltd | Pyrazoloquinoline Derivative |
| JP2015531401A (ja) * | 2011-10-10 | 2015-11-02 | ハー・ルンドベック・アクチエゼルスカベット | イミダゾピラジノン骨格を有するｐｄｅ９ｉ |
| AP2014007820A0 (en) * | 2012-01-26 | 2014-07-31 | Lundbeck & Co As H | PDE9 inhibitors with imidazo triazinone backbone |
| WO2013142269A1 (en) * | 2012-03-19 | 2013-09-26 | Envivo Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| US9585877B2 (en) | 2012-05-08 | 2017-03-07 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| MD20140130A2 (ro) | 2012-06-29 | 2015-04-30 | Pfizer Inc. | 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2 |
| WO2014024125A1 (en) | 2012-08-08 | 2014-02-13 | Celon Pharma S.A. | Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors |
| WO2014127331A1 (en) | 2013-02-17 | 2014-08-21 | Intra-Cellular Therapies, Inc. | Novel uses |
| CN105121440B (zh) | 2013-04-05 | 2017-05-24 | 卫材R&D管理有限公司 | 吡唑并喹啉衍生物的盐及其晶体 |
| RU2655172C2 (ru) | 2013-04-05 | 2018-05-24 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Пиридинилпиразолохинолиновые соединения |
| CN103626774B (zh) * | 2013-11-20 | 2015-11-04 | 苏州明锐医药科技有限公司 | 伊鲁替尼的制备方法 |
| ES2663622T3 (es) | 2013-12-17 | 2018-04-16 | Pfizer Inc. | Novedosas 1H-pirrolo[2,3-b]piridinas 3,4-disustituidas y 7H-pirrolo[2,3-c]piridacinas 4,5-disustituidas como inhibidores de LRRK2 |
| JP6591530B2 (ja) | 2014-08-07 | 2019-10-16 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| ES2915200T3 (es) * | 2014-09-17 | 2022-06-21 | Intra Cellular Therapies Inc | Derivados de 7,8-dihidro-[2H]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5H)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC) |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| RU2702732C1 (ru) | 2014-12-06 | 2019-10-10 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| EP3226870B1 (en) | 2014-12-06 | 2019-09-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2017538769A (ja) | 2014-12-22 | 2017-12-28 | ファイザー・インク | プロスタグランジンｅｐ３受容体の拮抗薬 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| PT3865484T (pt) | 2015-07-07 | 2024-01-30 | H Lundbeck As | Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas |
| WO2017046675A1 (en) | 2015-09-14 | 2017-03-23 | Pfizer Inc. | Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors |
| JP6983161B2 (ja) | 2015-09-15 | 2021-12-17 | プラクシス・バイオリサーチ・エルエルシー | フェンカンファミンのプロドラッグ |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| KR20250010141A (ko) | 2015-10-16 | 2025-01-20 | 애브비 인코포레이티드 | (3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드및 이의 고체상 형태의 제조 방법 |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND METHOD |
| TWI729109B (zh) * | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| CN114903900A (zh) | 2016-07-06 | 2022-08-16 | 伊马拉公司 | 用于治疗外周疾病的pde9抑制剂 |
| JP7112413B2 (ja) | 2016-10-18 | 2022-08-03 | ハー・ルンドベック・アクチエゼルスカベット | Ｐｄｅ１阻害剤としてのイミダゾピラジノン、ピラゾロピリミジノンおよびピラゾロピリジノン |
| CN109803658A (zh) | 2016-10-28 | 2019-05-24 | H.隆德贝克有限公司 | 包含用于治疗精神疾病和/或认知障碍的咪唑并吡嗪酮的组合治疗 |
| US10912773B2 (en) | 2016-10-28 | 2021-02-09 | H. Lundbeck A/S | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors |
| EP3562828A1 (en) | 2016-12-28 | 2019-11-06 | Dart NeuroScience LLC | Substituted pyrazolopyrimidinone compounds as pde2 inhibitors |
| EA201992721A1 (ru) | 2017-05-26 | 2020-09-10 | Имара Инк. | Способы получения и применения ингибиторов pde9 |
| AU2018278422B2 (en) | 2017-06-01 | 2022-03-17 | Eisai R&D Management Co., Ltd. | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
| IL270395B (en) | 2017-06-01 | 2022-08-01 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| JP7293129B2 (ja) | 2017-06-01 | 2023-06-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｐｄｅ９阻害剤を含む医薬組成物 |
| BR112019023595A2 (pt) * | 2017-06-01 | 2020-05-26 | Eisai R&D Management Co., Ltd. | Agente terapêutico da demência combinando derivados de pirazoloquinolina e memantina |
| EP3634964B1 (en) | 2017-06-08 | 2022-02-23 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde9 inhibitors |
| MX2020005447A (es) | 2017-11-27 | 2020-12-03 | Dart Neuroscience Llc | Compuestos de furanopirimidina sustituida como inhibidores de pde1. |
| WO2019152697A1 (en) | 2018-01-31 | 2019-08-08 | Intra-Cellular Therapies, Inc. | Novel uses |
| CN110357888A (zh) * | 2018-04-09 | 2019-10-22 | 南京药捷安康生物科技有限公司 | 杂环磷酸二酯酶抑制剂及其用途 |
| EP3801526B1 (en) | 2018-05-25 | 2023-12-27 | Imara Inc. | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one |
| CN112996512B (zh) | 2018-08-31 | 2025-01-03 | 卡都瑞恩医药公司 | 用于治疗镰状细胞病的pde9抑制剂 |
| EP3866808A4 (en) * | 2018-10-21 | 2023-04-12 | Intra-Cellular Therapies, Inc. | NEW USES |
| KR102706457B1 (ko) * | 2018-12-06 | 2024-09-11 | 한국화학연구원 | Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도 |
| CN111471059B (zh) | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
| EP4297868A4 (en) | 2021-02-23 | 2025-01-08 | Hoth Therapeutics, Inc. | USE OF APREPITANT TO TREAT ALZHEIMER'S |
| KR20240119299A (ko) * | 2021-12-16 | 2024-08-06 | 화이자 인크. | 피라졸로[3,4-d]피리미딘 화합물의 고체 형태 |
| EP4674841A2 (en) * | 2022-02-16 | 2026-01-07 | Duke Street Bio Limited | Pharmaceutical compound |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020156277A1 (en) | 2001-04-20 | 2002-10-24 | Fick David B. | Synthesis and methods of use of purine analogues and derivatives |
| EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| EP1444009A1 (en) * | 2001-11-02 | 2004-08-11 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| WO2004008230A2 (en) * | 2002-07-12 | 2004-01-22 | Massachusetts Institute Of Technology | Reconfigurable microphotonics devices via deformable membrane platform |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| DE10238722A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| US7051174B2 (en) * | 2002-09-24 | 2006-05-23 | International Business Machines Corporation | Method, system, and program for restoring data in cache |
| EP1553947A4 (en) | 2002-10-21 | 2006-11-29 | Bristol Myers Squibb Co | QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS |
| US7111287B2 (en) * | 2003-01-10 | 2006-09-19 | International Business Machines Corporation | Global processor resource assignment in an assembler |
| ES2289377T3 (es) | 2003-03-18 | 2008-02-01 | The Jordanian Pharmaceutical Manufacturing Co. Ltd. | Nuevas pirazolopirimidonas y su uso como inhibidores de pde. |
| JP4887139B2 (ja) | 2003-03-25 | 2012-02-29 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
| DE10320785A1 (de) * | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
-
2008
- 2008-05-05 MY MYPI20094735A patent/MY147330A/en unknown
- 2008-05-05 KR KR1020097025802A patent/KR101222330B1/ko active Active
- 2008-05-05 MX MX2009011830A patent/MX2009011830A/es active IP Right Grant
- 2008-05-05 PL PL08737600T patent/PL2152712T3/pl unknown
- 2008-05-05 AU AU2008249750A patent/AU2008249750B2/en active Active
- 2008-05-05 WO PCT/IB2008/001125 patent/WO2008139293A1/en not_active Ceased
- 2008-05-05 RS RS20120094A patent/RS52166B/sr unknown
- 2008-05-05 EA EA200901373A patent/EA016510B1/ru unknown
- 2008-05-05 NZ NZ580904A patent/NZ580904A/en unknown
- 2008-05-05 EP EP08737600A patent/EP2152712B1/en active Active
- 2008-05-05 SI SI200830543T patent/SI2152712T1/sl unknown
- 2008-05-05 JP JP2010507997A patent/JP4579346B2/ja active Active
- 2008-05-05 AP AP2009005048A patent/AP2524A/xx active
- 2008-05-05 ME MEP-2009-330A patent/ME00954B/me unknown
- 2008-05-05 BR BRPI0811280A patent/BRPI0811280B8/pt active IP Right Grant
- 2008-05-05 HR HR20120105T patent/HRP20120105T1/hr unknown
- 2008-05-05 GE GEAP200811556A patent/GEP20125405B/en unknown
- 2008-05-05 DK DK08737600.0T patent/DK2152712T3/da active
- 2008-05-05 UA UAA200911482A patent/UA94660C2/ru unknown
- 2008-05-05 AT AT08737600T patent/ATE540954T1/de active
- 2008-05-05 CA CA2687035A patent/CA2687035C/en active Active
- 2008-05-05 PT PT08737600T patent/PT2152712E/pt unknown
- 2008-05-05 CN CN2008800242732A patent/CN101687876B/zh active Active
- 2008-05-05 ES ES08737600T patent/ES2377849T3/es active Active
- 2008-05-08 PE PE2008000812A patent/PE20090247A1/es active IP Right Grant
- 2008-05-09 US US12/118,062 patent/US7964607B2/en active Active
- 2008-05-09 AR ARP080101964A patent/AR066502A1/es active IP Right Grant
- 2008-05-09 PA PA20088779901A patent/PA8779901A1/es unknown
- 2008-05-09 TW TW097117227A patent/TWI362262B/zh active
- 2008-05-09 CL CL2008001374A patent/CL2008001374A1/es unknown
-
2009
- 2009-11-05 IL IL201977A patent/IL201977A/en not_active IP Right Cessation
- 2009-11-05 CR CR11095A patent/CR11095A/es unknown
- 2009-11-05 ZA ZA2009/07776A patent/ZA200907776B/en unknown
- 2009-11-06 CU CU2009000184A patent/CU23834B1/es active IP Right Grant
- 2009-11-06 TN TNP2009000471A patent/TN2009000471A1/fr unknown
- 2009-11-09 NI NI200900204A patent/NI200900204A/es unknown
- 2009-11-10 EC EC2009009728A patent/ECSP099728A/es unknown
- 2009-11-10 DO DO2009000258A patent/DOP2009000258A/es unknown
- 2009-11-10 GT GT200900294A patent/GT200900294A/es unknown
- 2009-11-10 CO CO09127785A patent/CO6241157A2/es active IP Right Grant
- 2009-11-11 SV SV2009003411A patent/SV2009003411A/es unknown
- 2009-11-11 MA MA32341A patent/MA31373B1/fr unknown
-
2012
- 2012-02-06 CY CY20121100125T patent/CY1112332T1/el unknown
Non-Patent Citations (1)
| Title |
|---|
| FRANK WUNDER, ADRIAN TERSTEEGEN, ANNEGRET REBMANN, CHRISTINA ERB, THOMAS FAHRIG AND MARTIN HENDRIX: "Characterization of the First Potent and Selective PDE9 Inhibitor Using a cGMP Reporter Cell Line", MOL PHARMACOL, vol. 68, no. 6, 2005, page 1775-1781, XP002491746, page 1777 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2524A (en) | Amino-heterocyclic compounds | |
| GB0704407D0 (en) | Compounds | |
| GB0704394D0 (en) | Compounds | |
| GB0724951D0 (en) | Compounds | |
| GB0705672D0 (en) | Compounds | |
| GB0706173D0 (en) | Compounds | |
| GB0706168D0 (en) | Compounds | |
| GB0706188D0 (en) | Compounds | |
| GB0706174D0 (en) | Compounds | |
| GB0706187D0 (en) | Compounds | |
| GB0706189D0 (en) | Compounds | |
| GB0706190D0 (en) | Compounds | |
| GB0706170D0 (en) | Compounds | |
| GB0704939D0 (en) | Compounds | |
| GB0703756D0 (en) | Compounds | |
| GB0701955D0 (en) | Compounds | |
| GB0701985D0 (en) | Compounds | |
| GB0701969D0 (en) | Compounds | |
| GB0700283D0 (en) | Compounds | |
| GB0701968D0 (en) | Compounds | |
| GB0701981D0 (en) | Compounds | |
| GB0701956D0 (en) | Compounds | |
| GB0701197D0 (en) | Compounds | |
| GB0706290D0 (en) | Compounds | |
| GB0701984D0 (en) | Compounds |